U.S. Markets closed

U.S. lawmakers request federal inquiry into AbbVie's actions with drug Humira -statement

·1 min read

WASHINGTON, May 18 (Reuters) - Three chairs of U.S. House of Representatives committees are calling for Federal Trade Commission inquiry into AbbVie Inc.'s actions with its drug Humira, saying in a statement released on Tuesday that a multi-year congressional investigation has raised questions about its pricing of the anti-inflammatory biologic.

Documents reviewed during the investigation indicated that AbbVie found ways to delay the development of biosimilar drugs, which could provide cheaper competition, the chairs of the House Oversight and Judiciary committees and Antitrust subcommittee said.

"We ask that you investigate whether this delay was the result of anticompetitive conduct in violation of U.S. law," they wrote in the letter requesting an FTC inquiry. (Reporting by Lisa Lambert Editing by Chizu Nomiyama)